NICE adds Opdivo to CDF for head and neck cancer

The U.K.’s NICE said Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) will be available on the country’s Cancer Drugs Fund for patients with metastatic head and neck cancer who have not responded to chemotherapy within six months.

The list price of the PD-1 inhibitor is £1,097 ($1,459) every two weeks; the pharma will provide the drug to NHS England at an undisclosed discount. Patients must stop treatment at two years or earlier if the cancer spreads further...